

Supplementary Table S4. Accuracy testing.

No	Steroid	Concentration in blood [nM]					Level 1	Bias (SD) [%] Intraday/interday (n=6)	Level 2	Bias (SD) [%] Intraday/interday (n=6)	Level 3	Bias (SD) [%] Intraday/interday (n=6)
							Added		Added		Added	
		M	F	L	P	U	[pg inj. /nM]	[pg inj. /nM]	[pg inj. /nM]			
1	Preg	5.1	8.4	9.2	18	74	500/79	1.5(0.62) / 2.7(5.8)	125/20	-7.9(1.2) / 2.3(7.1)	31.25/4.9	4.3(0.55) / -1(8.6)
2	Preg17	12	13	8.4	24	33	500/75	7.3(0.023) / 3.5(3.4)	125/19	-14(0.2) / -0.84(11)	31.25/4.7	1.8(0.28) / -0.37(4.4)
3	Preg16α	0.43	0.43	0.33	0.81	7.1	31.3/4.7	5.8(0.2) / 3.8(11)	7.81/1.2	1.3(1.6) / 2.7(9.5)	1.95/0.29	-3.1(2) / -1.8(6.1)
4	DHPreg20α	2.3	3.4	4.2	4	5.1	125/20	-12(2.2) / 3.5(8.5)	31.3/4.9	-0.015(1.9) / 2.5(6.9)	7.81/1.2	-3.5(1.5) / -0.12(7.5)
5	DHEA	10	15	12	18	7.7	500/87	4.5(0.21) / -0.79(6.9)	125/22	-3.9(0.27) / -0.7(3.2)	31.25/5.4	9.9(1.5) / -1.1(8.6)
6	DHEA7α	1.3	1.5	0.96	0.91	2	31.3/5.1	-4.3(0.25) / 1.2(8.9)	7.81/1.3	1.7(1.2) / 1.2(8.3)	1.95/0.32	0.12(2.7) / 1.2(8.4)
7	DHEA7ο	1.1	0.41	0.39	0.53	0.79	31.3/5.2	-6.7(3.3) / -2.3(6.1)	7.81/1.3	-2.1(0.95) / -0.35(9.9)	1.95/0.32	8.7(9.7) / 4.1(12)
8	DHEA7β	0.48	0.25	0.4	0.17	0.33	31.3/5.1	-13(0.06) / -0.82(9.2)	7.81/1.3	0.013(1.2) / 2.1(2.5)	1.95/0.32	7.7(3.9) / 2(13)
9	5-Adiol	2.5	2.3	1.9	1.5	0.44	31.3/5.4	-2.4(0.47) / 2.9(13)	7.81/1.3	6.9(1.2) / 2.4(10)	1.95/0.34	0.65(1.1) / -0.43(5)
10	AT7α	0.37	0.44	0.28	0.098	0.016	31.3/5.1	-3.5(1.2) / 1(6.8)	7.81/1.3	4.2(0.8) / 6.4(2.9)	1.95/0.32	-1.9(3.9) / -2.8(6.3)
11	AT7β	0.31	0.35	0.25	0.068	0.019	31.3/5.1	-3.4(0.62) / 2.2(7)	7.81/1.3	4.7(0.89) / 4.2(5.6)	1.95/0.32	-2.2(1.3) / -0.49(3.8)
12	AT16α	0.51	0.45	0.51	0.8	3.1	31.3/5.1	2.2(0.21) / -2.9(0.74)	7.81/1.3	-5.6(4.1) / 1.8(3.9)	1.95/0.32	-1.5(10) / 2.8(1.3)
13	P	0.24	0.25	12	320	2300	2000/320	0.64(0.83) / 2.1(5)	125/20	-5(0.13) / -3.3(7.1)	1.95/0.31	-1.8(0.35) / -0.024(7)
14	P17	2.8	1.1	3.2	18	99	500/76	4.6(0.55) / 1.1(5)	125/19	-14(1.2) / -7.5(5.9)	7.81/1.2	5.1(11) / 2.5(6.4)
15	DHP17α20α	1.5	0.68	1	8.4	26	500/75	8.7(0.64) / 1.7(5.7)	31.3/4.7	-13(0.2) / -6.9(12)	7.81/1.2	6.1(1.7) / 1.3(3.6)
16	P16α	0.76	0.48	0.96	19	140	500/76	7.8(0.13) / 1.2(11)	125/19	-11(0.38) / -10(2.8)	7.81/1.2	-0.54(0.83) / -4.2(9.2)
17	DHP20α	0.21	0.29	4.9	92	99	500/79	2.6(0.42) / 6.6(5.4)	31.3/5	3.3(0.63) / 1.5(10)	7.81/1.2	-4.7(0.67) / -2.9(8.6)
18	A4	2.6	2.7	2.3	8.6	15	125/22	-2.9(0.55) / -4.9(4.9)	31.3/5.5	6.9(0.19) / -0.39(13)	7.81/1.4	-4.8(6.4) / -4.3(8.9)
19	T	2.6	2.7	2.3	8.6	15	125/22	-12(0.12) / -0.66(6.2)	31.3/5.4	2.5(2.6) / 5.3(9.1)	7.81/1.4	1.7(0.82) / -13(15)
20	T16α	---	---	---	4.2	11	125/21	1.6(1.3) / -3.2(7.7)	31.3/5.1	-1.8(0.64) / 4.9(4.9)	7.81/1.3	-0.81(14) / 1.2(14)
21	DHT5α	1.5	0.51	0.5	0.58	0.14	31.3/5.4	4.3(1.4) / -0.51(6.8)	7.81/1.3	2(1.6) / -0.54(8.6)	1.95/0.34	-2.3(2.9) / 3(4.9)
22	E1	0.16	0.24	0.26	48	120	500/93	3.1(0.41) / 2.9(9.9)	7.81/1.4	4.4(2) / -0.012(7.5)	1.95/0.36	-7.9(1.7) / 3.7(8.7)
23	E2	0.1	0.38	0.42	68	33	500/92	-8.7(1.7) / -4.9(9.2)	31.3/5.8	-0.52(1.5) / -4.2(13)	1.95/0.36	12(8.3) / -9.8(9.5)
24	E3	---	---	---	22	415	2000/350	-2.2(0.039) / -1.1(8)	500/87	4.6(1.3) / -8.7(6.3)	125/22	-2.5(0.31) / -6.4(13)
25	DHP5α	---	---	---	61	170	2000/320	3.6(0.51) / 0.56(6.2)	500/79	-5.3(1) / 2.5(5.9)	125/20	-7.4(0.42) / 2.3(11)

Supplementary Table S4., continued.

No	Steroid	Concentration in blood [nM]					Level 1	Bias (SD) [%] Intraday/interday (n=6)	Level 2	Bias (SD) [%] Intraday/interday (n=6)	Level 3	Bias (SD) [%] Intraday/interday (n=6)
		M	F	L	P	U	Added [pg inj. /nM]		Added [pg inj. /nM]		Added [pg inj. /nM]	
26	THP3 α 5 α	0.068	0.24	0.87	32	24	500/79	1.4(1.1) / 5.9(5.5)	31.3/4.9	-0.017(0.5) / -0.48(12)	1.95/0.31	12(8.3) / 4(9.5)
27	THP3 β 5 α	0.25	0.59	0.83	18	38	500/79	-0.52(0.98) / 0.36(9.1)	31.3/4.9	3.3(2.7) / -0.32(10)	7.81/1.2	3.9(3.1) / -2.7(5.8)
28	DHP5 β	---	---	---	3.1	45	500/79	6.9(2.1) / 3.6(9.3)	125/20	-13(2.6) / -6.3(3.9)	31.25/4.9	5.3(0.18) / 1.1(6.2)
29	THP3 α 5 β	---	---	---	20	29	500/79	2.5(0.12) / 0.25(8.9)	125/20	-6.5(0.69) / 1.3(13)	31.25/4.9	5.3(2.2) / 0.51(9.4)
30	THP3 β 5 β	---	---	---	1.4	3.4	31.3/4.9	2.9(1.6) / 1.9(8.2)	7.81/1.2	-13(3.9) / -3.2(10)	1.95/0.31	12(0.97) / -3.2(8.5)
31	THP5 α 20 α	0.24	0.6	1.4	34	62	500/79	1.4(0.93) / 1.6(8.3)	7.81/1.2	2.9(1.8) / 0.46(6.9)	1.95/0.31	-5.2(5.2) / -2.6(5.3)
32	PD3 α 5 α 20 α	0.26	0.41	1.1	25	9.8	500/78	4.4(0.95) / 8.2(5.7)	31.3/4.9	5.3(3.1) / -1.7(8.5)	7.81/1.2	-0.48(5.9) / 0.57(13)
33	PD3 β 5 α 20 α	1.4	2.4	3.6	73	90	2000/310	2.2(1.4) / 2.9(2.2)	500/78	3.4(0.83) / -0.028(5.6)	31.3/4.9	-13(1.7) / -11(11)
34	THP5 β 20 α	---	---	---	2.3	40	500/79	4.8(0.84) / 1.5(4.7)	125/20	-11(0.94) / -0.14(5.3)	31.25/4.9	10(0.76) / 1.5(10)
35	PD3 α 5 β 20 α	0.28	0.23	0.35	8.2	11	125/20	-8.5(0.75) / 3.2(8.1)	31.3/4.9	11(0.68) / 5.5(7.2)	7.81/1.2	-7.3(8.7) / -1.4(9.9)
36	PD3 β 5 β 20 α	---	---	---	0.85	2.3	125/20	-2.3(1.7) / 4.3(12)	31.3/4.9	4.8(0.92) / -3(9.4)	7.81/1.2	-2.8(5) / 1.9(6.3)
37	PD3 α 5 α 17	0.077	0.066	0.063	0.69	0.9	7.81/1.2	1.3(0.26) / -1.8(6.4)	1.95/0.29	11(0.58) / 0.038(15)	0.488/0.073	-11(5) / -5.2(24)
38	PD3 α 5 β 17	0.12	0.072	0.18	1.4	1.7	31.3/4.7	3(1.4) / -4.5(5.5)	7.81/1.2	2.7(1.1) / -3.6(3.9)	1.95/0.29	-1.8(4.8) / 0.92(8.8)
39	PT3 α 5 α 17 α 20 α	0.28	0.2	0.22	0.23	0.13	31.3/4.7	-4.3(0.19) / 1(5.1)	7.81/1.2	-1.1(1.6) / -6.1(4.1)	1.95/0.29	3(0.1) / -2.9(8.2)
40	PT3 β 5 α 17 α 20 α	0.24	0.31	0.33	0.24	0.12	31.3/4.7	-2.7(0.94) / -0.96(7.5)	7.81/1.2	4(0.25) / -4.2(7.1)	1.95/0.29	-2.3(0.46) / -6.3(11)
41	PT3 α 5 β 17 α 20 α	1.5	1.5	1.7	7.3	3	31.3/4.7	-2.4(0.4) / 0.55(3.8)	7.81/1.2	1.2(2.1) / -8(8.7)	1.95/0.29	0.21(1.7) / -1.6(11)
42	DHA5 α	0.27	0.32	0.24	0.49	0.6	31.3/5.4	12(0.47) / 4.5(12)	7.81/1.4	-3.6(3.2) / -2.8(7.7)	1.95/0.34	-2(1.3) / 3.1(4.6)
43	THA3 α 5 α	0.46	0.31	0.29	0.7	0.4	31.3/5.4	7.8(0.043) / 0.72(10)	7.81/1.3	4.8(0.54) / 2.7(6.5)	1.95/0.34	-6.4(1.2) / -2.8(3.8)
44	THA3 β 5 α	0.31	0.4	0.33	0.57	0.31	31.3/5.4	5.4(0.51) / 2.3(2.5)	7.81/1.3	11(2.7) / 2.7(10)	1.95/0.34	-10(4) / -3.9(7.1)
45	THA3 α 5 β	0.25	0.31	0.24	0.54	0.63	7.81/1.3	4.3(1.1) / 3.3(6.8)	1.95/0.34	2.8(0.34) / -6.6(12)	0.488/0.084	-8.8(4.9) / -11(8.2)
46	AD3 α 5 α 17 β	0.29	0.084	0.078	0.13	0.038	7.81/1.3	11(0.59) / 5.6(8)	1.95/0.33	4.3(1.2) / -6.1(8.4)	0.488/0.084	-10(9) / -0.081(6.7)
47	AD3 β 5 α 17 β	5.1	8.4	9.2	18	74	7.81/1.3	6.1(1.7) / 3.5(4.2)	1.95/0.33	-1.3(1.9) / 5.6(8.2)	0.488/0.084	1.7(7.9) / -21(29)
48	AD3 α 5 β 17 β	5.1	8.4	9.2	18	74	7.81/1.3	6.1(1.7) / 8(5.9)	1.95/0.33	-1.3(1.9) / -4(2.9)	0.488/0.084	1.7(7.9) / 1.8(2.5)
49	F	310	300	310	680	260	10000/1400	3.1(1.7) / 3.3(2.8)	2000/280	-6.5(4.9) / -3(4.7)	500/69	3(1.8) / 5.5(5.8)
50	E	51	49	50	140	310	10000/1400	4.1(0.25) / 1.7(5.2)	2000/280	-8.5(1.4) / 1.4(6.5)	500/69	3.8(4.6) / -2.6(7.4)

Supplementary Table S4., continued.

No	Steroid	Concentration in blood [nM]					Level 1	Bias (SD) [%] Intraday/interday (n=6)	Level 2	Bias (SD) [%] Intraday/interday (n=6)	Level 3	Bias (SD) [%] Intraday/interday (n=6)
		M	F	L	P	U	Added [pg inj. /nM]		Added [pg inj. /nM]		Added [pg inj. /nM]	
51	B	13	14	11	74	18	500/72	2.8(1.6) / 5.6(5.7)	125/18	-12(0.21) / -2.5(7.5)	31.3/4.5	-1.5(0.45) / 9.6(8.3)
52	DOF	0.19	0.22	0.24	0.75	0.76	31.3/4.5	-10(2.1) / -6.6(9.5)	7.81/1.1	5.2(0.43) / 0.94(9.3)	1.95/0.28	3.8(0.3) / -4.4(9.5)
53	DOC	---	---	---	3.3	7.1	125/19	-13(1.5) / -2(10)	31.3/4.7	-7.4(1.6) / -6(7.6)	7.81/1.2	7.5(0.66) / 2(10)
54	THB3 α 5 α	0.27	0.37	0.27	0.37	---	31.3/4.5	-10(5.2) / -1.8(4.4)	7.81/1.1	3(0.89) / 3.9(11)	1.95/0.28	6.5(8.5) / 2.7(12)
55	THB3 α 5 β	0.5	0.51	0.47	0.48	0.16	31.3/4.5	1.9(2.5) / 3.4(9.5)	7.81/1.1	3.2(0.49) / 2.2(7.6)	1.95/0.28	1(1.5) / -9.8(12)
56	11OHA4	77	75	47	270	100	2000/330	-4.4(0.82) / 3.3(5.2)	500/83	6.8(0.95) / -2.1(7.7)	125/21	-4.9(0.78) / -1.4(8.6)
57	THA3 α 5 α 11 β	8.2	3.7	3.7	1.2	1.3	125/20	-1.5(0.043) / 1.2(3)	31.3/5.1	0.13(0.21) / 0.54(8.6)	7.81/1.3	4.5(3.8) / -0.94(3.8)
58	THA3 β 5 α 11 β	0.49	0.26	0.26	0.1	0.17	125/20	-1.3(0.2) / -8.9(15)	31.3/5.1	-0.5(0.5) / 0.68(9.6)	7.81/1.3	5(0.44) / 2.2(11)
59	THA3 α 5 β 11 β	1.5	0.68	1	8.4	26	7.81/1.3	8.5(2.2) / 2.5(3.1)	1.95/0.32	13(0.76) / -7.8(21)	0.488/0.08	-14(11) / -28(37)
60	PregC	250	250	300	530	4400	10000/1600	-1.2(0.93) / -7.7(2.3)	2000/320	-0.034(1.1) / 5.1(6.1)	500/79	3.8(1.3) / -2.5(5.8)
61	Preg17C	41	42	59	110	5800	10000/1500	-2.4(0.49) / -5.6(3.5)	500/75	4.8(0.71) / -2.4(9.3)	125/19	-4.4(6.3) / 0.45(5.7)
62	DHPreg20 α C	1400	990	1500	790	2300	10000/1500	0.39(0.47) / -7.4(2.9)	2000/300	-0.87(0.5) / 3.5(7)	500/75	0.5(1.6) / 2.1(8.1)
63	DHEAC	4700	4600	4400	2100	5000	10000/1700	2.5(0.99) / -7.2(3.2)	2000/350	-5.7(1.1) / 7.8(5.3)	500/87	3.4(2) / -3.6(4.8)
64	5-AdiolC	3400	2900	2300	360	4500	10000/1700	0.53(1.2) / -5.4(2.6)	2000/340	0.57(0.78) / 8(4.8)	500/86	5.9(1.4) / -3.8(3.4)
65	AT16 α C	50	67	61	170	2300	2000/330	-6.9(0.97) / -3(6)	500/82	3.8(0.78) / 0.81(0.78)	125/20	0.5(1.2) / 1.3(7.9)
66	DHP17 α 20 α C	13	20	21	---	---	500/75	5.4(0.58) / -2.6(3.7)	125/19	-7.1(1.9) / -11(5.5)	31.3/4.7	-14(3.9) / 5.3(7.2)
67	DHP20 α C	2.9	3.6	8.2	30	140	2000/320	2.6(1.3) / 4.9(2.1)	125/20	0.76(4.5) / -9.3(6.6)	7.81/1.2	3.8(3.2) / -1.5(6.1)
68	TC	---	---	---	19	51	500/87	-2.9(4.7) / 5.7(2.5)	125/22	2.2(5.8) / -0.54(7.3)	31.3/5.4	0.3(5.5) / -1.3(1.7)
69	EpiTC	---	---	---	16	410	2000/350	-2.9(4.7) / -4.5(3.6)	500/87	2.2(5.8) / 3.2(4)	125/22	0.3(5.5) / -1.3(3.8)
70	E1C	---	---	---	680	37	2000/370	6.9(1.2) / 3.5(6.2)	500/93	-2.3(1.5) / 1.1(5.1)	125/23	-13(3.8) / -0.6(10)
71	E2C	---	---	---	29	5.3	500/92	9.4(1.1) / 1.3(9.8)	125/23	-4.1(1.2) / 2(7.7)	31.3/5.8	9.3(2.6) / -3.7(5.5)
72	E3C	---	---	---	16	410	10000/1700	-8.1(0.6) / 1.6(2.4)	2000/350	-3.7(0.68) / -5.8(5.5)	500/87	8(0.86) / 7.4(8.1)
73	THP3 α 5 α C	7.3	14	68	1500	410	10000/1600	1.9(1.1) / -9.8(19)	2000/310	-3.4(0.58) / -2.3(5.5)	125/20	-13(2.8) / 1(6.3)
74	THP3 β 5 α C	17	25	45	1000	490	2000/310	-6(0.46) / -3.7(6.3)	500/79	3.6(0.83) / 7(3.2)	125/20	-6.2(1.4) / -5.1(4.7)

Supplementary Table S4., continued.

No	Steroid	Concentration in blood [nM]					Level 1	Bias (SD) [%] Intraday/interday (n=6)	Level 2	Bias (SD) [%] Intraday/interday (n=6)	Level 3	Bias (SD) [%] Intraday/interday (n=6)
		M	F	L	P	U	Added [pg inj. /nM]		Added [pg inj. /nM]		Added [pg inj. /nM]	
75	THP3 α 5 β C	31	41	70	880	450	10000/1600	-5.9(0.9) / -7.9(3.9)	2000/310	2.5(0.78) / -0.45(9.6)	125/20	-3.9(2.9) / 1.4(5.8)
76	THP3 β 5 β C	3.9	12	14	240	160	2000/310	-3.9(1.1) / -3.2(8.3)	125/20	-8.8(3.2) / 0.7(4.5)	31.3/4.9	-9.3(2.9) / -3.4(4.1)
77	THP5 α 20 α C	0.63	1.4	14	130	180	2000/310	-1.9(0.51) / 3.4(6.2)	125/20	-9(2) / -2.1(11)	7.81/1.2	10(2.6) / -4.3(7.4)
78	PD3 α 5 α 20 α C	33	62	270	5100	3000	10000/1600	-4.4(0.98) / -7.2(1.1)	500/78	-3.3(0.41) / -3.1(6.8)	125/20	-14(4.2) / -3.5(6.4)
79	PD3 β 5 α 20 α C	500	2700	7800	65000	35000	10000/1600	0.28(2.1) / -8.9(2.1)	2000/310	-0.72(1.5) / 9.8(8.1)	500/78	0.57(4.2) / -2.8(8.1)
80	THP5 β 20 α C	---	---	---	35	98	2000/310	-11(0.48) / 2.6(5.4)	500/79	14(2) / 0.22(8.5)	125/20	-4.2(2.8) / 1.6(9.4)
81	PD3 α 5 β 20 α C	20	52	220	1700	2000	10000/1600	-9.2(2.1) / -11(1.7)	2000/310	4(1.4) / 4(10)	125/20	-12(4) / -1.8(6.3)
82	PD3 β 5 β 20 α C	24	120	190	1200	990	10000/1600	-7.1(0.67) / -8.4(7)	2000/310	-2.3(0.97) / -2.7(7.2)	125/20	-12(3.1) / 1.2(0.99)
83	PD3 α 5 α 17C	4.4	2.2	6.1	22	9.5	500/75	5.6(0.8) / 7.2(4.7)	125/19	-9.8(1.6) / 2.4(7.1)	31.3/4.7	3.4(2.4) / 0.99(8.2)
84	PD3 α 5 β 17C	18	12	26	100	69	2000/300	-11(0.64) / 1.1(7.3)	500/75	15(1.6) / 4.7(3.8)	125/19	-2.3(1.9) / 0.52(5.9)
85	PT3 α 5 α 17 α 20 α C	---	---	---	39	82	2000/300	0.93(0.83) / 3(8.8)	500/74	-2.9(1.4) / -0.6(9.9)	125/19	2.1(0.001) / -2.2(4.5)
86	PT3 β 5 α 17 α 20 α C	---	---	---	7.7	5.2	125/19	-4.3(1.5) / -5.2(5.6)	31.3/4.7	-11(0.58) / 6.1(8.1)	7.81/1.2	11(4.5) / 4.1(1.1)
87	PT3 α 5 β 17 α 20 α C	---	---	---	360	390	10000/1500	-11(1.6) / 1.2(4.7)	2000/300	15(2.7) / -3.9(10)	125/19	1.9(1.1) / 2.6(6.7)
88	THA3 α 5 α C	1900	2700	3200	630	100	10000/1700	5.1(1.4) / -4.8(1.3)	2000/340	-12(0.8) / 9.8(2.3)	500/86	7.9(1.7) / -4.6(3.8)
89	THA3 β 5 α C	510	510	500	150	55	10000/1700	-0.57(0.74) / -9.2(3.8)	2000/340	0.34(0.55) / 5.2(7.1)	125/22	-0.82(1.7) / -1.7(5.2)
90	THA3 α 5 β C	100	130	110	62	20	2000/340	-2(0.75) / 5.3(7.4)	500/86	-1.4(0.95) / 0.74(7)	125/22	-7.3(1) / -3.4(8.7)
91	THA3 β 5 β C	54	73	99	10	2.5	500/86	14(0.7) / 3.4(7.3)	125/22	-5.1(1.7) / -2.7(8.2)	7.81/1.3	10(5) / 2.4(7.3)
92	AD3 α 5 α 17 β C	170	78	76	31	33	2000/340	-1.7(0.95) / 2.1(7.6)	125/22	-13(1.4) / -1.3(7.5)	31.3/5.4	-8.4(1.6) / -3.1(3.8)
93	AD3 β 5 α 17 β C	250	150	200	29	15	2000/340	4.4(1.2) / 2.7(5.9)	125/22	-9.8(1.6) / 3.7(9.2)	31.3/5.4	-7.5(2) / 0.84(5.1)
94	AD3 α 5 β 17 β C	24	22	24	5.6	8.9	500/86	14(0.45) / 1.6(8.2)	125/22	-11(2.7) / 0.22(5.1)	31.3/5.4	-8.7(2.9) / -0.89(10)
95	AD3 β 5 β 17 β C	1.2	1.2	2.1	0.69	1.6	125/22	-13(1.2) / 0.72(9.9)	31.3/5.4	-9(1.6) / -1.3(9.2)	7.81/1.3	9.6(4.4) / -4(5.7)
96	THB3 α 5 α C	---	---	98	40	20	10000/1400	-4.2(1.7) / -3.4(5.9)	2000/290	9.9(13) / 6.5(1.2)	500/71	5.3(12) / 2.2(7.3)
97	THB3 α 5 β C	---	---	---	47	---	10000/1400	-2.8(2.2) / -2.9(9.2)	125/18	6.8(8.5) / 2.8(11)	31.3/4.5	-2.4(13) / -6.4(4.8)
98	THA3 α 5 α 11 β C	44	38	37	19	14	500/82	9.6(0.82) / 4.5(5.5)	125/20	4.8(0.95) / 0.46(5.5)	31.3/5.1	3.2(1.3) / -1.9(1.6)
99	THA3 β 5 α 11 β C	2.2	2.3	2	1.1	10	125/20	4.5(1.3) / 2.4(6.3)	31.3/5.1	-2.5(2.9) / -1.6(5)	7.81/1.3	4.4(4.8) / -6.3(2.2)
100	THA3 α 5 β 11 β C	9.2	15	15	3.2	1.1	125/20	4.3(2.2) / 0.8(4.8)	31.3/5.1	0.61(2.6) / -2.3(3.5)	7.81/1.3	0.82(4) / -3.7(6.8)